Home » Authors » Peter O'Donnell

Articles by Peter O'Donnell

EU Medicines Agency Adds To Scientific Working Parties

April 18, 2001

By Peter O'Donnell

EMEA Sets Out Plans Covering Biotechnology For Next 2 Years

April 4, 2001

By Peter O'Donnell

New Group Formed To Assess Drug Competitiveness Issues

April 4, 2001

By Peter O'Donnell

EMEA Sets Out Plans Covering Biotechnology For Next 2 Years

April 4, 2001

By Peter O'Donnell

New Group Formed To Assess Drug Competitiveness Issues

April 4, 2001

By Peter O'Donnell

European Orphan Drugs Initiative Generates Applications, Support

March 28, 2001

By Peter O'Donnell

European Council Joins Other Bodies In Supporting Biotech

March 28, 2001

By Peter O'Donnell

European Orphan Drugs Initiative Generates Applications, Support

March 28, 2001

By Peter O'Donnell

European Council Joins Other Bodies In Supporting Biotech

March 28, 2001

By Peter O'Donnell

Commission, Parliament Give Boosts To EU Biotechnology

March 21, 2001

By Peter O'Donnell

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 18, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...